Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria

Abstract To prevent bleeding in severe haemophilia A [SHA, defined as factor VIII (FVIII) activity < 1%] regular prophylactic FVIII replacement therapy is required, and the benefits of factor products with extended half-life (EHL) over traditional standard half-life (SHL) are still being debated....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cihan Ay, Clemens Feistritzer, Joachim Rettl, Gerhard Schuster, Anna Vavrovsky, Leonard Perschy, Ingrid Pabinger
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/8e84b37a487c40b5a14d05ed968045e9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!